Phase 2
N=40
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Upper Respiratory Tract Infections
Bottom Line
View on ClinicalTrials.gov: NCT01883427 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcome: Primary: Respiratory Infectious Symptoms — 9; 13; 10; 13 days — p=>0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Placebo (Drug); Glucose oxidase (Drug)
- Age
- Pediatric
- Sex
- All
- Sponsor
- Krister Tano
- Primary completion
- May 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Respiratory Infectious Symptoms |
9; 13; 10; 13; 6; 8 | >0.05 |
Summary
To investigate if use of glucosoxidas nasal spray can reduce the number of days with upper respiratory tract infections in children beyond 4 years.
Eligibility Criteria
Inclusion Criteria
- Children below 4 years of age
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01883427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.